Professor Toren serves on the faculty of the Sackler School of Medicine in Tel Aviv in Hematolory. His research interests include diagnosis and treatment of childhood cancer, Pearson Syndrome, and pediatric medulloblastoma.
Education:
Academic Degree: Full Professor in Hematology
1977 - 1983 Degree of MD, The Sackler School of Medicine, Tel-Aviv University
1985 - 1990 Residency, Department of Pediatrics, The Chaim Sheba Medical Center, Tel-Hashomer.
1990 Passed the Israeli Pediatrics Board Examination: Registered Specialist in Pediatrics.
1990 - 1992 Residency, Department of Hematology, The Chaim Sheba Medical Center, Tel-Hashomer.
1992 Passed the Israeli Hematology Board Examination: Registered Specialist in Hematology
1995 Registered specialist in Pediatric Hemato-Oncology
1996 Visiting Professor: Bone Marrow Transplantation Department, Hadassah University Hospital, Jerusalem
1996 Member of the Ministry of Health Cord Blood Committee
1998 - 2002 PhD, Faculty of Medicine, Department of Human Genetics,Tel-Aviv University. Dissertation: Assessing the genetic changes in the Fechtner Syndrome
Acknowledging departments for specialization
2002 - Present Head of Pediatric Hemato-Oncology and BMT, The Chaim Sheba Medical Center, Tel-Hashomer.
2006 - 2007 MHA, Recanati School of Business, Tel-Aviv University
2009 Member of the Ministry of Health Palliative Care Committee
2006 - 2010 Head, the Division of Hematology, Sackler school of Medicine, Tel Aviv University
2004 - 2018 Member of the subcommittee of the Scientific council for authorization of Pediatric and Hematology Department
2017 - present Member of the Israeli Ministry of Health "[Pharmaceutical] Basket" Committee
Licensure
1984 General Physician
1990 Specialist in Pediatrics
1993 Specialist in Hematology
1995 Specialist in Pediatric Hemato-Oncology
Recent Grants
|
Years
|
Investigator (Principal / other)
|
Granted by Institute/Company
|
Title
|
Total Amount
|
|
2015-2016
|
Amos Toren and Ruthy Shai
|
Dotan Center Idea Grant
|
cMYC regulation by miR-34 in Burkitt’s lymphoma lacking an identifiable MYC rearrangement.
|
100,000 NIS
|
|
2016
|
Amos Toren and Ruthy Shai
|
Gesner Grant
|
Novel brain cancer treatment
|
80,000 NIS
|
|
2016-2017
|
Amos Toren, Shany Caspi, Nira Bloom
|
Dotan Center Idea Grant
|
Priming Cytokine Induced Killer (CIK) Cells for Hematological Malignancies
|
100,000 NIS
|
|
2017
|
Amos Toren
|
The Champ Foundation
|
CD34+ cells enriched with blood cells derived healthy mitochondria as a treatment for Pearson Syndrome
|
130,000 USD
|
|
2018
|
Amos Toren
|
The Champ Foundation
|
Promoting clinical development of
Mitochondrial Augmentation Therapy for Pearson Syndrome Patients
|
130,000 USD
|
|
2018
|
Amos Toren
|
The research fund of the Chief Scientist in the Ministry of Health
|
Knowledge based diagnosis and treatment of childhood cancer
|
300,000 NIS
|
|
2018
|
Amos Toren
|
Translational Research Sheba
|
Pediatric Medulloblastoma long noncoding RNA markers
|
40.000 USD
|
|
2021-2024
|
Amos Toren and Ruthy Shai
|
Israel Innovation Authority (KAMIN)
|
Preventing metastasis in medulloblastoma
|
230,000 USD
|
Here is a link to the list of publications for Dr. Toren in PubMed . PubMed is a database that includes a listing of scientific articles in the fields of medicine and life sciences.
